Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 02/13/2026 | CALL | $1,057.50 | 398 | +311 | +357.47% |
| 02/13/2026 | CALL | $1,075.00 | 530 | +227 | +74.92% |
| 02/13/2026 | CALL | $1,140.00 | 392 | +165 | +72.69% |
| 02/20/2026 | CALL | $1,025.00 | 246 | +163 | +196.39% |
| 02/20/2026 | PUT | $750.00 | 681 | +140 | +25.88% |
| 02/20/2026 | PUT | $900.00 | 2,132 | +107 | +5.28% |
| 02/20/2026 | CALL | $860.00 | 18 | -385 | -95.53% |
| 02/20/2026 | CALL | $850.00 | 13 | -514 | -97.53% |
| 02/20/2026 | CALL | $810.00 | 13 | -535 | -97.63% |
| 02/13/2026 | CALL | $1,050.00 | 332 | -555 | -62.57% |
| 02/20/2026 | CALL | $720.00 | 0 | -555 | -100.00% |
| 02/20/2026 | CALL | $820.00 | 5 | -838 | -99.41% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.74% | 26M | 11.45B |
| Vanguard 500 Index Fund | 1.92% | 18.23M | 8.03B |
| Vanguard/Primecap Fund | 1.56% | 14.85M | 6.54B |
| Fidelity 500 Index Fund | 0.91% | 8.65M | 3.81B |
| SPDR S&P 500 ETF Trust | 0.90% | 8.54M | 3.76B |
| Vanguard Specialized-Health Care Fund | 0.80% | 7.64M | 3.37B |
| iShares Core S&P 500 ETF | 0.74% | 7.04M | 3.1B |
| Washington Mutual Investors Fund | 0.73% | 6.95M | 3.06B |
| Growth Fund Of America Inc | 0.71% | 6.7M | 2.95B |
| Select Sector SPDR Fund-Health Care | 0.67% | 6.41M | 2.82B |
What Is One of the Best Pharmaceutical Stocks to Own for the Next 10 Years?
02/14 03:25 pm
The Motley Fool
Read moreCRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens
02/13 02:45 pm
Benzinga
Read moreDid Eli Lilly Just Make a Deal for Its Next Blockbuster Drug?
02/13 11:15 am
The Motley Fool
Read moreMeet the 6.3% Yield Dividend Stock That Could Soar in 2026
02/13 07:32 am
The Motley Fool
Read moreEli Lilly Builds $1.5 Billion Inventory Of Experimental Weight-Loss Pill As FDA Decision Looms
02/13 06:36 am
Benzinga
Read moreNovo Nordisk Plans Wegovy Vial Launch To Counter Eli Lilly, Target Broader Obesity Market
02/12 02:02 pm
Benzinga
Read moreEli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know.
02/12 06:10 am
The Motley Fool
Read moreI Predicted That ExxonMobil Would Join the $1 Trillion Club by 2030, But the Stock Is Already Up 24% in 2026. Is the High-Yield Dividend Stock Still a Buy Now?
02/11 09:05 pm
The Motley Fool
Read more3 Reasons to Buy Eli Lilly Stock
02/11 12:15 pm
The Motley Fool
Read moreDisney Has Its Next CEO
02/11 11:30 am
The Motley Fool
Read moreViking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore
02/11 02:15 am
The Motley Fool
Read moreMissed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
02/10 09:11 pm
The Motley Fool
Read moreFDA cardiovascular indication for semaglutide led to short-term uptake but persistent treatment gaps among high-risk patients, new Truveta study finds
02/10 10:00 am
GlobeNewswire Inc.
Read moreNovo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment?
02/09 03:30 pm
The Motley Fool
Read moreOver 60% of Eli Lilly's Revenue Comes From Its GLP-1 Drugs. Should Investors Be Worried?
02/09 12:30 pm
The Motley Fool
Read moreCarterra Launches Industry’s First 48-channel HT-SPR Platform for Advanced Label-free Biomolecular Screening and Characterization
02/09 12:00 pm
GlobeNewswire Inc.
Read moreEli Lilly Bets $2.4 Billion On Small Biotech To Boost Future Cell Treatments
02/09 10:11 am
Benzinga
Read moreMissed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
02/07 10:30 pm
The Motley Fool
Read more3 Things Investors Need to Know About the Healthcare Sector in 2026
02/07 10:13 am
The Motley Fool
Read moreEli Lilly vs Novo Nordisk: The 1 Figure Investors Shouldn't Ignore
02/06 03:15 pm
The Motley Fool
Read moreCVS Caremark Replaces Amgen And Eli Lilly's Branded Drugs, Expands Biosimilar Strategy For Weak Bone Disorder
02/06 02:52 pm
Benzinga
Read moreAnti-Obesity Drugs Market to Reach US$195.99 Billion by 2036 as GLP-1 Therapies Drive a Structural Shift in Weight Management
02/06 06:00 am
GlobeNewswire Inc.
Read moreAmazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings.
02/05 09:15 pm
The Motley Fool
Read moreEli Lilly's 2026 Outlook Push Back Demand Fears: Analyst
02/05 02:44 pm
Benzinga
Read moreEli Lilly: Why Investors Are Rewarding It as Novo Slips
02/05 11:38 am
Investing.com
Read moreObesity Treatment Market Size to Reach USD 75.69 Billion by 2033 as the Treatment Offers a Comprehensive Evaluation of Therapeutic Developments Globally
02/05 05:00 am
GlobeNewswire Inc.
Read moreWhy Eli Lilly Stock Soared Today
02/04 11:18 pm
The Motley Fool
Read moreNovo Nordisk Faces a Reality Check as Pricing Pressure Hits 2026 Forecasts
02/04 03:22 pm
Investing.com
Read moreIn Weight Loss Drug Battle For 2026, Eli Lilly Pulls Ahead Of Novo Nordisk
02/04 03:02 pm
Benzinga
Read moreQ4 Earnings Summary: Eli Lilly and AbbVie Beat, Uber Mixed
02/04 12:01 pm
Investing.com
Read moreStock Market Today: Dow Futures Gain, Nasdaq Drops As Trump Signs Bill To End Partial Shutdown— AMD, SMCI, LLY In Focus (UPDATED)
02/04 09:53 am
Benzinga
Read moreFDA Moves To Bring Pharma Manufacturing Back To US With New Pilot
02/02 02:11 pm
Benzinga
Read more3 Headwinds Facing Pfizer in 2026
02/02 07:32 am
The Motley Fool
Read moreDemand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally?
01/30 07:24 pm
The Motley Fool
Read moreNovo Nordisk Outspends Eli Lilly On Wegovy, Ozempic Ads After Supply Crunch Eases
01/30 01:57 pm
Benzinga
Read moreShould You Buy Eli Lilly Before Feb. 4?
01/30 08:15 am
The Motley Fool
Read moreEli Lilly Teams Up With Two Biotechs To Target Autoimmune Disease, Hearing Loss In Deals Worth $3 Billion
01/29 02:58 pm
Benzinga
Read morePrediction: Artificial Intelligence (AI) Will Reshape This Industry by 2030. This Stock Could Lead.
01/29 09:05 am
The Motley Fool
Read moreCan This Beaten-Down AI Stock Bounce Back in 2026?
01/28 10:01 pm
The Motley Fool
Read moreMissed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy.
01/28 09:30 pm
The Motley Fool
Read moreNVIDIA Sets Conference Call for Fourth-Quarter Financial Results
01/28 06:00 pm
GlobeNewswire Inc.
Read moreChronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics | DelveInsight
01/28 02:00 pm
GlobeNewswire Inc.
Read moreSeamless Therapeutics Announces Global Research Collaboration with Lilly to Develop Programmable Recombinase-based Therapeutics for Hearing Loss
01/28 08:00 am
GlobeNewswire Inc.
Read moreMedicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle
01/28 06:51 am
Benzinga
Read more1 Biotech Stock Set to Rebound in 2026
01/28 02:30 am
The Motley Fool
Read moreAtopic Dermatitis Market to Reach USD 12.97 Billion by 2034, Growing at 7.75% CAGR
01/27 11:00 am
GlobeNewswire Inc.
Read moreWhere Will Eli Lilly Be in 10 Years?
01/27 10:07 am
The Motley Fool
Read more